Products
FOB Rapid Test
Multi-Drug Test
Strep A Rapid Test
Single Drug Test
9 in 1 Respiratory Viruses Combo Test
CRP Semi-Quontitative Rapid Test

GREYLYNX

Advanced In-Vitro Diagnostics for a Smarter, Faster Healthcare Future Zhejiang Greylynx Biotech Co., Ltd. is a Chinese-German joint venture founded in 2021 in Hangzhou. In just a few years, Greylynx has become a trusted manufacturer of high-quality in‑vitro diagnostic tests-delivering reliable solutions for professionals across global healthcare markets.

Our portfolio covers a wide range of essential diagnostic needs, including cardiac markers, infectious disease assays, hormone tests, and DOA panels. Every product is designed to support accurate, timely, and actionable clinical decisions.

Driving Innovation in Point-of-Care Diagnostics At Greylynx, we are committed to redefining the future of point-of-care testing. By combining cutting‑edge technologies, rigorous quality standards, and intelligent diagnostic workflows, we aim to make diagnostics faster, more precise, and more accessible worldwide. We continuously push forward to enhance the performance, efficiency, and reliability of POCT systems—empowering healthcare providers with tools that help improve patient outcomes.

    Why Greylynx?
  • German-Chinese engineering synergy for global-quality standards
  • Comprehensive POCT-focused portfolio of high-impact diagnostic markers
  • Rapid, accurate, and intelligent test results tailored for modern healthcare
  • Agile innovation culture driving new solutions to emerging medical needs
    • Greylynx is dedicated to shaping a smarter diagnostic ecosystem-one where speed, accuracy, and reliability meet.